Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series.
Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series.
复制标题
日本东京的 COVID-19 危重患者：单中心病例系列。
DOI：
10.1016/j.jiac.2020.10.019
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Nakamura-Uchiyama F
中科院分区：
文献类型：
--
作者：
Miike S;Sakamoto N;Washino T;Kosaka A;Kuwahara Y;Ishida T;Hikone M;Oyabu T;Kojima H;Iwabuchi S;Nakamura-Uchiyama F
在我们之前的研究中，我们报道了一名2019冠状病毒病（COVID-19）患者成功接受体外膜氧合治疗。在日本，关于COVID-19危重患者的临床过程和结果的文献数据有限。本研究旨在描述日本东京地区COVID-19危重患者的临床病程和结局。这是一项单中心病例系列研究。回顾性分析采用机械通气（MV）治疗的COVID-19患者。收集基线特征、住院治疗和结果的数据。2020年2月2日至6月30日期间，14例危重患者接受了MV治疗。大多数患者为男性，并伴有合并症，尤其是高血压或糖尿病；35.7%超重，21.4%肥胖。大多数患者入院时出现呼吸困难。中位病程为10.5 d， 28天死亡率为35.7%。在4例死亡的COVID-19患者中，死亡原因是呼吸衰竭。与其他国家以前的报告一样，东京需要重症监护的COVID-19患者死亡率仍然很高。危重症患者MV启动时机及特异性治疗需要进一步研究。
We reported, in our previous study, a patient with coronavirus disease 2019 (COVID-19) who was successfully treated with extracorporeal membrane oxygenation. Data on clinical courses and outcomes of critically ill patients with COVID-19 in Japan are limited in the literature. This study aimed to describe the clinical courses and outcomes of critically ill patients with COVID-19 in Tokyo, Japan. This is a single-center case series study. Patients with COVID-19 treated with mechanical ventilation (MV) were reviewed retrospectively. Data on baseline characteristics, in-hospital treatment, and outcomes were collected. Between February 2, 2020, and June 30, 2020, 14 critically ill patients with COVID-19 were treated with MV. Most patients were male and had comorbidities, especially hypertension or diabetes; 35.7% were overweight and 21.4% were obese. The majority of the patients had dyspnea on admission. The median duration of MV was 10.5 days, and the 28-day mortality rate was 35.7%. In the four patients with COVID-19 who died, the cause of death was respiratory failure. As in previous reports from other countries, the mortality rate of patients with COVID-19 requiring intensive care remains high in Tokyo. Further study on the appropriate timing of MV initiation and specific treatments for critically ill patients with COVID-19 is needed.